HRP20201506T1 - Uporaba kanabidiolne kiseline u liječenju epilepsije - Google Patents
Uporaba kanabidiolne kiseline u liječenju epilepsije Download PDFInfo
- Publication number
- HRP20201506T1 HRP20201506T1 HRP20201506TT HRP20201506T HRP20201506T1 HR P20201506 T1 HRP20201506 T1 HR P20201506T1 HR P20201506T T HRP20201506T T HR P20201506TT HR P20201506 T HRP20201506 T HR P20201506T HR P20201506 T1 HRP20201506 T1 HR P20201506T1
- Authority
- HR
- Croatia
- Prior art keywords
- cbda
- effective amount
- therapeutically effective
- use according
- epilepsy
- Prior art date
Links
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 title claims 26
- 206010015037 epilepsy Diseases 0.000 title claims 5
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 title 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 4
- 229950011318 cannabidiol Drugs 0.000 claims 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 4
- 241000218236 Cannabis Species 0.000 claims 2
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 claims 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 2
- 229960004242 dronabinol Drugs 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- 208000003078 Generalized Epilepsy Diseases 0.000 claims 1
- 208000034308 Grand mal convulsion Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 claims 1
- -1 inhaler Substances 0.000 claims 1
- 239000006193 liquid solution Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000006200 vaporizer Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. Terapijski efikasna količina kanabidiolne kiseline (CBDA) za uporabu u liječenju epilepsije, naznačena time što je CBDA u obliku visoko pročišćenog ekstrakta kanabisa, tako da je CBDA prisutna u više od 98% ukupnog ekstrakta (tež./tež.) ili je proizvedena sintetički.
2. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 1, naznačena time što je epilepsija generalizirana epilepsija.
3. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačena time što epilepsiju karakteriziraju toničko-klonički napadaji.
4. Terapijski efikasna količina CBDA za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je terapijski efikasna količina najmanje 0,1 mg.
5. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 1, naznačena time što visoko pročišćeni ekstrakt sadrži manje od 1% (tež./tež.) tetrahidrokanabinola (THC) ili tetrahidrokanabinolne kiseline (THCA).
6. Terapijski efikasna količina CBDA za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se CBDA koristi istovremeno sa jednim ili više drugih kanabinoida.
7. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 6, naznačena time što se CBDA koristi sa kanabidiolom (CBD).
8. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 7, naznačena time što je odnos CBDA: CBD u opsegu od 9:1 do 1:9 (CBDA: CBD).
9. Terapijski efikasna količina CBDA za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se CBDA koristi istovremeno sa jednim ili više drugih antiepileptičkih lijekova (AED).
10. Terapijski efikasna količina CBDA za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se CBDA koristi u dozi manjoj od 400 mg.
11. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 10, naznačena time što se CBDA koristi u dozi od 1 mg do 100 mg.
12. Pripravak za uporabu u liječenju epilepsije koji sadrži terapijski efikasnu količinu kanabidiolne kiseline (CBDA), i jedan ili više farmaceutski prihvatljivih ekscipijenata, naznačena time što je CBDA u obliku visoko pročišćenog ekstrakta kanabisa, tako da je CBDA prisutna u više od 98% ukupnog ekstrakta (tež./tež.) ili je proizvedena sintetički.
13. Pripravak za uporabu prema patentnom zahtjevu 12, koji je formuliran za dostavu u vidu oralne tekuće otopine, čvrste supstance, polu-čvrste supstance, gela, spreja, aerosola, inhalatora, isparivača, klistira ili čepića.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1514079.1A GB2541191A (en) | 2015-08-10 | 2015-08-10 | Use of cannabinoids in the treatment of epilepsy |
PCT/GB2016/052340 WO2017025712A1 (en) | 2015-08-10 | 2016-07-29 | Use of cannabinoids in the treatment of epilepsy |
EP16747593.8A EP3334422B1 (en) | 2015-08-10 | 2016-07-29 | Use of cannabidiolic acid in the treatment of epilepsy |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201506T1 true HRP20201506T1 (hr) | 2021-02-05 |
Family
ID=54200465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201506TT HRP20201506T1 (hr) | 2015-08-10 | 2020-09-21 | Uporaba kanabidiolne kiseline u liječenju epilepsije |
Country Status (18)
Country | Link |
---|---|
US (2) | US11147783B2 (hr) |
EP (2) | EP3769755B1 (hr) |
JP (2) | JP6949822B2 (hr) |
AU (1) | AU2016305545B2 (hr) |
CA (1) | CA2992802C (hr) |
CY (1) | CY1123351T1 (hr) |
DK (1) | DK3334422T3 (hr) |
ES (1) | ES2820333T3 (hr) |
GB (1) | GB2541191A (hr) |
HR (1) | HRP20201506T1 (hr) |
HU (1) | HUE051476T2 (hr) |
LT (1) | LT3334422T (hr) |
MX (2) | MX2018001472A (hr) |
PL (1) | PL3334422T3 (hr) |
PT (1) | PT3334422T (hr) |
RS (1) | RS60852B1 (hr) |
SI (1) | SI3334422T1 (hr) |
WO (1) | WO2017025712A1 (hr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
BR112020004947A2 (pt) * | 2017-09-19 | 2020-09-15 | Zynerba Pharmaceuticals, Inc. | canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos |
GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
BR112020020850A2 (pt) * | 2018-04-09 | 2021-01-19 | Ellevet Sciences | Extrato de cânhamo para tratamento da dor em animais |
GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
CN113766841A (zh) * | 2019-04-30 | 2021-12-07 | 格林威草本产品有限责任公司 | 大麻素组合物和用法 |
PE20221403A1 (es) | 2019-08-27 | 2022-09-15 | Herbolea Biotech S P A | Concentrado y aislado de cannabinoide, metodo para su obtencion y uso |
US20220304943A1 (en) * | 2019-10-28 | 2022-09-29 | Canopy Growth Corporation | Flowable cannabinoid compositions having high effective concentrations |
GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
EP4157259A1 (en) * | 2020-05-24 | 2023-04-05 | Asana Bio Group Ltd. | Compositions of cannabinoids and methods of using same |
WO2022049232A1 (en) | 2020-09-04 | 2022-03-10 | Herbolea Biotech S.P.A. | Thc-free cannabinoid concentrate, method of obtaining the same and use thereof |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
IL311852A (en) * | 2021-10-11 | 2024-05-01 | Neurotech Int Ltd | Preparations and methods for the treatment of neurological disorders |
WO2023060302A1 (en) * | 2021-10-11 | 2023-04-20 | Neurotech International Ltd | Compositions and methods for treating neurological disorders with combination products |
US11551799B1 (en) * | 2022-04-05 | 2023-01-10 | Green Sky Creations LLC | Multi-stage release cannabinoid compositions |
WO2024059353A1 (en) * | 2022-09-12 | 2024-03-21 | Greenway Herbal Products, Llc | Cannabinoid and omega fatty acid compositions and methods of using |
WO2024073812A1 (en) * | 2022-10-06 | 2024-04-11 | Neurotech International Ltd | Methods for treating paediatric neurological disorders |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6403126B1 (en) | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
US6949582B1 (en) | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
DE10296335T5 (de) | 2001-02-14 | 2004-04-15 | G W Pharma Ltd., Salisbury | Pharmazeutische Formulierungen |
GB0202385D0 (en) | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
EP1482917B1 (en) | 2002-02-01 | 2019-05-08 | GW Pharma Limited | Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
ITPD20020138A1 (it) | 2002-05-24 | 2003-11-24 | Matteo Bevilacqua | Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima. |
DE10226494A1 (de) | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
ES2377819T3 (es) | 2002-08-14 | 2012-04-02 | Gw Pharma Limited | Formulaciones líquidas cannabinoides para administración mucosal |
MXPA05001621A (es) | 2002-08-14 | 2005-08-19 | Gw Pharma Ltd | Extraccion de cannabinoides farmaceuticamente activos de materiales vegetales. |
US10538373B2 (en) | 2002-08-14 | 2020-01-21 | Gw Pharma Limited | Pharmaceutical formulation |
GB0222077D0 (en) * | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
US20040110828A1 (en) | 2002-11-27 | 2004-06-10 | Chowdhury Dipak K. | Tetrahydrocannabinol compositions and methods of manufacture and use thereof |
US9168278B2 (en) | 2004-11-16 | 2015-10-27 | Gw Pharma Limited | Use for cannabinoid |
GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
US20070060638A1 (en) | 2005-08-26 | 2007-03-15 | Olmstead Mary C | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
GB2434312B (en) | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
US9877928B2 (en) | 2006-05-30 | 2018-01-30 | Air Systems, Inc. | Gear drive damper |
GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
EP2046290A4 (en) | 2006-08-04 | 2011-08-17 | Insys Therapeutics Inc | AQUEOUS DRONABINOL FORMULATIONS |
WO2008021394A2 (en) | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
US20080188461A1 (en) | 2007-02-01 | 2008-08-07 | Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
CN101040855A (zh) | 2007-04-12 | 2007-09-26 | 杨喜鸿 | 含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用 |
GB2448535A (en) | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
WO2008144475A1 (en) | 2007-05-17 | 2008-11-27 | California Pacific Medical Center | Methods and compositions for treating cancer |
GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
EP2023121A1 (en) | 2007-07-06 | 2009-02-11 | Bp Oil International Limited | Optical cell |
GB2450753B (en) | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
CA2694325C (en) | 2007-07-30 | 2015-09-22 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
US20090181080A1 (en) | 2007-08-06 | 2009-07-16 | Insys Therapeutics Inc. | Oral cannabinnoid liquid formulations and methods of treatment |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
GB2459637B (en) | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
BRPI0910094B1 (pt) | 2008-03-26 | 2021-08-10 | Stichting Sanammad | Composição de goma de mascar, e, blíster |
GB2478072B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2478074B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
KR101701544B1 (ko) | 2009-06-29 | 2017-02-01 | 벤더 아날리티컬 홀딩 비.브이. | 폴리옥사졸린 및 생리활성제를 포함하는 약물 전달 시스템 |
GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
US8735374B2 (en) | 2009-07-31 | 2014-05-27 | Intelgenx Corp. | Oral mucoadhesive dosage form |
GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途 |
GB2479153B (en) | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
US20120034297A1 (en) | 2010-08-04 | 2012-02-09 | Gruenenthal Gmbh | Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
WO2012033478A1 (en) | 2010-09-07 | 2012-03-15 | Murty Pharmaceuticals, Inc. | An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
CA2737447A1 (en) * | 2011-04-27 | 2012-10-27 | Antony Paul Hornby | Hayley's comet |
GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
WO2013032351A1 (en) | 2011-08-26 | 2013-03-07 | BIAL - PORTELA & Cª, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2496687A (en) | 2011-11-21 | 2013-05-22 | Gw Pharma Ltd | Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells |
US9254272B2 (en) | 2011-11-30 | 2016-02-09 | Sutter West Bay Hospitals | Resorcinol derivatives |
DE102012105063C5 (de) | 2012-06-12 | 2023-09-14 | Thc Pharm Gmbh The Health Concept | Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen |
US9345771B2 (en) | 2012-10-04 | 2016-05-24 | Insys Development Company, Inc. | Oral cannabinoid formulations |
CN103110582A (zh) | 2013-03-04 | 2013-05-22 | 上海医药工业研究院 | 大麻酚类化合物微乳剂及其制备方法 |
US9095554B2 (en) | 2013-03-15 | 2015-08-04 | Biotech Institute LLC | Breeding, production, processing and use of specialty cannabis |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
US20150181924A1 (en) | 2013-10-31 | 2015-07-02 | Michael R. Llamas | Cannabidiol liquid composition for smoking |
US9259449B2 (en) | 2014-01-07 | 2016-02-16 | Joshua Michael Raderman | Method for modifying THC content in a lipid-based extract of cannabis |
US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
CN106999598B (zh) | 2014-05-29 | 2022-02-08 | 鲜切发展有限责任公司 | 稳定的大麻素类化合物制剂 |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
US20160000843A1 (en) * | 2014-07-01 | 2016-01-07 | MJAR Holdings, LLC | High cannabidiol cannabis strains |
WO2016022936A1 (en) | 2014-08-07 | 2016-02-11 | Murty Pharmaceuticals, Inc. | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
CA2859934A1 (en) * | 2014-09-22 | 2016-03-22 | A. Paul Hornby | Hayley's comet ii |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2531280A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
EP3209312A1 (en) | 2014-10-21 | 2017-08-30 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
US20180303791A1 (en) | 2014-11-26 | 2018-10-25 | One World Cannabis Ltd | Synergistic use of cannabis for treating multiple myeloma |
US9375417B2 (en) * | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
US10172786B2 (en) | 2014-12-16 | 2019-01-08 | Axim Biotechnologies, Inc. | Oral care composition comprising cannabinoids |
US10751300B2 (en) | 2015-01-25 | 2020-08-25 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
EP3270896A4 (en) | 2015-03-19 | 2018-09-12 | One World Cannabis Ltd. | Preparations of cannabis emulsions and methods thereof |
EP3307266A4 (en) | 2015-06-11 | 2019-01-16 | One World Cannabis Ltd | Novel CANNABINOID COMBINATION THERAPIES FOR MULTIPLE MYELOMA (MM) |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2551985B (en) | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2572125B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
GB2572126B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
GB2572737A (en) | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
-
2015
- 2015-08-10 GB GB1514079.1A patent/GB2541191A/en not_active Withdrawn
-
2016
- 2016-07-29 DK DK16747593.8T patent/DK3334422T3/da active
- 2016-07-29 SI SI201630922T patent/SI3334422T1/sl unknown
- 2016-07-29 HU HUE16747593A patent/HUE051476T2/hu unknown
- 2016-07-29 JP JP2018507504A patent/JP6949822B2/ja active Active
- 2016-07-29 AU AU2016305545A patent/AU2016305545B2/en active Active
- 2016-07-29 MX MX2018001472A patent/MX2018001472A/es unknown
- 2016-07-29 EP EP20182674.0A patent/EP3769755B1/en active Active
- 2016-07-29 ES ES16747593T patent/ES2820333T3/es active Active
- 2016-07-29 LT LTEP16747593.8T patent/LT3334422T/lt unknown
- 2016-07-29 CA CA2992802A patent/CA2992802C/en active Active
- 2016-07-29 US US15/751,563 patent/US11147783B2/en active Active
- 2016-07-29 WO PCT/GB2016/052340 patent/WO2017025712A1/en active Application Filing
- 2016-07-29 PT PT167475938T patent/PT3334422T/pt unknown
- 2016-07-29 EP EP16747593.8A patent/EP3334422B1/en active Active
- 2016-07-29 RS RS20201104A patent/RS60852B1/sr unknown
- 2016-07-29 PL PL16747593T patent/PL3334422T3/pl unknown
-
2018
- 2018-02-02 MX MX2021000814A patent/MX2021000814A/es unknown
-
2020
- 2020-09-17 CY CY20201100881T patent/CY1123351T1/el unknown
- 2020-09-21 HR HRP20201506TT patent/HRP20201506T1/hr unknown
-
2021
- 2021-09-09 US US17/470,382 patent/US11684598B2/en active Active
- 2021-09-21 JP JP2021153168A patent/JP7303267B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
GB201514079D0 (en) | 2015-09-23 |
LT3334422T (lt) | 2020-11-25 |
CA2992802C (en) | 2023-09-19 |
MX2018001472A (es) | 2018-04-24 |
WO2017025712A1 (en) | 2017-02-16 |
HUE051476T2 (hu) | 2021-03-01 |
EP3334422A1 (en) | 2018-06-20 |
JP6949822B2 (ja) | 2021-10-13 |
MX2021000814A (es) | 2021-03-25 |
JP2018527341A (ja) | 2018-09-20 |
AU2016305545B2 (en) | 2021-12-09 |
ES2820333T3 (es) | 2021-04-20 |
EP3769755B1 (en) | 2023-05-24 |
RS60852B1 (sr) | 2020-10-30 |
US20180228751A1 (en) | 2018-08-16 |
US20220062211A1 (en) | 2022-03-03 |
EP3334422B1 (en) | 2020-07-01 |
US11147783B2 (en) | 2021-10-19 |
PL3334422T3 (pl) | 2020-12-28 |
PT3334422T (pt) | 2020-09-29 |
DK3334422T3 (da) | 2020-09-28 |
JP7303267B2 (ja) | 2023-07-04 |
EP3769755A1 (en) | 2021-01-27 |
JP2021191797A (ja) | 2021-12-16 |
CA2992802A1 (en) | 2017-02-16 |
AU2016305545A1 (en) | 2018-02-08 |
US11684598B2 (en) | 2023-06-27 |
GB2541191A (en) | 2017-02-15 |
SI3334422T1 (sl) | 2020-11-30 |
CY1123351T1 (el) | 2021-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201506T1 (hr) | Uporaba kanabidiolne kiseline u liječenju epilepsije | |
HRP20201325T1 (hr) | Uporaba kanabidiola u liječenju kompleksa tuberozne skleroze | |
HRP20201230T1 (hr) | Uporaba kanabinoida u liječenju atoničkih napadaja kod lennox-gastaut sindroma | |
CO2018013654A2 (es) | Composiciones nasales de cannabidiol | |
MX2023007033A (es) | Extractos de cannabis y metodos de preparacion y uso de la misma. | |
MX2021006094A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
NZ726746A (en) | Stable cannabinoid formulations | |
MX2019001286A (es) | Composicion de cannabis. | |
ECSP17085659A (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
MX2021009646A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
CA2582289C (en) | Inhibition of tumour cell migration | |
GB201111261D0 (en) | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders | |
JP2013523708A5 (hr) | ||
GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
BR112015030315A2 (pt) | derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo | |
EA201591869A1 (ru) | Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой | |
DOP2015000005A (es) | Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
US20180338947A1 (en) | Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition | |
MX2021013285A (es) | Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa. | |
MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. |